Karen Wyckoff Rein In Sarcoma
Karen Wyckoff Rein In Sarcoma maintains strong assets and zero executive compensation, consistently operating with surpluses.
EIN: 200811343 · Fridley, MN · NTEE: H30 · Updated: 2026-03-28
Is Karen Wyckoff Rein In Sarcoma Legit?
Appears Legitimate
Assessment based on IRS 990 filings, spending patterns, and AI analysis. Not a guarantee of legitimacy. Full charity check →
Karen Wyckoff Rein In Sarcoma directs 85% of its spending to programs. This exceeds the industry benchmark of 65%, indicating strong mission focus.
About Karen Wyckoff Rein In Sarcoma
Karen Wyckoff Rein In Sarcoma (EIN: 200811343) is a nonprofit organization based in Fridley, MN, classified under NTEE code H30. The organization reported total revenue of $1.5M and total assets of $1.1M according to its most recent IRS 990 filing. This transparency report provides an AI-powered analysis of Karen Wyckoff Rein In Sarcoma's financial health, spending patterns, executive compensation, and overall mission effectiveness based on publicly available IRS data.
AI Transparency Report
Mission Effectiveness Score
NonprofitSpending's AI analysis rates Karen Wyckoff Rein In Sarcoma with a Mission Score of 92 out of 100 (Excellent). This score reflects the organization's overall financial transparency, program spending efficiency, and governance indicators derived from IRS 990 public filings.
Spending Breakdown
- admin: 10%
- programs: 85%
- fundraising: 5%
According to IRS 990 filings, Karen Wyckoff Rein In Sarcoma allocates its expenses as follows: admin: 10%, programs: 85%, fundraising: 5%. With 85% directed toward programs, this reflects a strong commitment to its charitable mission.
Executive Compensation Analysis
Executive compensation is consistently reported at 0% across all available filings, indicating that no officers receive salaries from the organization, which is highly commendable for an organization of its size with over $1 million in assets.
Executive compensation data is sourced from IRS 990 filings, which require nonprofits to disclose the compensation of officers, directors, trustees, and key employees. NonprofitSpending analyzes this data relative to the organization's total revenue and sector benchmarks to assess whether executive pay is reasonable.
Strengths
The following positive indicators were identified for Karen Wyckoff Rein In Sarcoma:
- Consistent 0% officer compensation, indicating high efficiency and dedication to mission.
- Strong asset growth from $387,852 in 2014 to $1,175,955 in 2023.
- Generally operates with a financial surplus, contributing to asset accumulation (e.g., $51,871 surplus in 2023).
- Consistent IRS 990 filing history (13 filings), demonstrating transparency.
- Low liabilities relative to assets, indicating strong financial solvency (e.g., $15,280 liabilities vs. $1,175,955 assets in 2023).
Frequently Asked Questions about Karen Wyckoff Rein In Sarcoma
Is Karen Wyckoff Rein In Sarcoma a legitimate charity?
Based on AI analysis of IRS 990 filings, Karen Wyckoff Rein In Sarcoma (EIN: 200811343) appears legitimate. Mission Score: 92/100. 0 red flags identified, 5 strengths noted.
How does Karen Wyckoff Rein In Sarcoma spend its money?
Karen Wyckoff Rein In Sarcoma directs 85% of its spending to programs and services. The remaining budget covers administration and fundraising costs.
Are donations to Karen Wyckoff Rein In Sarcoma tax-deductible?
Karen Wyckoff Rein In Sarcoma is registered as a tax-exempt nonprofit (EIN: 200811343). Donations to most 501(c)(3) organizations are tax-deductible. Consult a tax professional for your specific situation.
Is Karen Wyckoff Rein In Sarcoma a good charity?
Based on its financial data, Karen Wyckoff Rein In Sarcoma appears to be a very good charity. It consistently reports 0% officer compensation, maintains a healthy asset base, and generally operates with a surplus, indicating efficient use of funds and strong financial management.
How has the organization's revenue trended over time?
The organization's revenue has shown significant growth over the past decade, increasing from $239,134 in 2014 to $606,354 in 2023, with a peak of $954,475 in 2021, demonstrating strong fundraising capabilities.
What is the organization's asset growth like?
Karen Wyckoff Rein In Sarcoma has experienced substantial asset growth, increasing from $387,852 in 2014 to $1,175,955 in 2023, indicating effective financial stewardship and accumulation of resources.
Filing History
IRS 990 filing history for Karen Wyckoff Rein In Sarcoma showing financial trends over 13 years of public records:
Over 13 years of IRS 990 filings (2011–2023), Karen Wyckoff Rein In Sarcoma's revenue has grown by 228.1%, moving from $185K to $606K. Total assets increased by 450.7% over the same period, from $214K to $1.2M. Total functional expenses rose by 192.6%, from $190K to $554K. In its most recent filing year (2023), Karen Wyckoff Rein In Sarcoma reported a surplus of $52K, with revenue exceeding expenses. The organization holds $15K in liabilities against $1.2M in assets (debt-to-asset ratio: 1.3%), resulting in net assets of $1.2M.
| Year | Revenue | Expenses | Assets | Liabilities | Officer Comp. | |
|---|---|---|---|---|---|---|
| 2023 | $606K | $554K | $1.2M | $15K | — | — |
| 2022 | $717K | $737K | $1.2M | $90K | — | View 990 |
| 2021 | $954K | $540K | $1.2M | $17K | — | View 990 |
| 2020 | $446K | $489K | $795K | $0 | — | View 990 |
| 2019 | $575K | $476K | $808K | $2K | — | View 990 |
| 2018 | $428K | $484K | $710K | $2K | — | View 990 |
| 2017 | $489K | $401K | $774K | $3K | — | — |
| 2016 | $422K | $207K | $683K | $0 | — | View 990 |
| 2015 | $258K | $178K | $468K | $0 | — | View 990 |
| 2014 | $239K | $176K | $388K | $0 | — | View 990 |
| 2013 | $262K | $131K | $325K | $0 | — | View 990 |
| 2012 | $155K | $167K | $195K | $0 | — | View 990 |
| 2011 | $185K | $190K | $214K | $8K | — | View 990 |
Year-by-Year Financial Summary
- 2023: Revenue of $606K, expenses of $554K, and assets of $1.2M (revenue -15.4% year-over-year).
- 2022: Revenue of $717K, expenses of $737K, and assets of $1.2M (revenue -24.9% year-over-year).
- 2021: Revenue of $954K, expenses of $540K, and assets of $1.2M (revenue +114.2% year-over-year).
- 2020: Revenue of $446K, expenses of $489K, and assets of $795K (revenue -22.4% year-over-year).
- 2019: Revenue of $575K, expenses of $476K, and assets of $808K (revenue +34.2% year-over-year).
- 2018: Revenue of $428K, expenses of $484K, and assets of $710K (revenue -12.5% year-over-year).
- 2017: Revenue of $489K, expenses of $401K, and assets of $774K (revenue +16.0% year-over-year).
- 2016: Revenue of $422K, expenses of $207K, and assets of $683K (revenue +63.1% year-over-year).
- 2015: Revenue of $258K, expenses of $178K, and assets of $468K (revenue +8.1% year-over-year).
- 2014: Revenue of $239K, expenses of $176K, and assets of $388K (revenue -8.6% year-over-year).
- 2013: Revenue of $262K, expenses of $131K, and assets of $325K (revenue +68.2% year-over-year).
- 2012: Revenue of $155K, expenses of $167K, and assets of $195K (revenue -15.9% year-over-year).
- 2011: Revenue of $185K, expenses of $190K, and assets of $214K.
Data Sources and Methodology
This transparency report for Karen Wyckoff Rein In Sarcoma is generated by NonprofitSpending's AI analysis engine. The data is sourced from publicly available IRS 990 filings accessed through the ProPublica Nonprofit Explorer API and IRS electronic filing records. The Mission Score, spending breakdown, and other analytical insights are produced by artificial intelligence and should be used as one of multiple factors when evaluating a nonprofit organization.
IRS 990 forms are annual information returns that most tax-exempt organizations must file with the IRS. These forms provide detailed financial information including revenue, expenses, assets, liabilities, and compensation of officers. NonprofitSpending processes this data to provide accessible transparency reports for donors, researchers, and the general public.
Disclaimer
AI-generated analysis based on IRS public records. Not financial or legal advice. Verify information directly with the organization.